Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

XSSC:603392 Stock Report

Market Cap: CN¥92.6b

Beijing Wantai Biological Pharmacy Enterprise Valuation

Is 603392 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603392 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603392 (CN¥73.17) is trading above our estimate of fair value (CN¥3.01)

Significantly Below Fair Value: 603392 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603392?

Key metric: As 603392 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 603392. This is calculated by dividing 603392's market cap by their current revenue.
What is 603392's PS Ratio?
PS Ratio37.2x
SalesCN¥2.49b
Market CapCN¥92.57b

Price to Sales Ratio vs Peers

How does 603392's PS Ratio compare to its peers?

The above table shows the PS ratio for 603392 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.7x
300122 Chongqing Zhifei Biological Products
1.9x17.3%CN¥67.6b
603087 Gan & Lee Pharmaceuticals
9x27.4%CN¥26.8b
600161 Beijing Tiantan Biological Products
8.1x19.6%CN¥42.0b
300896 Imeik Technology DevelopmentLtd
19.8x19.2%CN¥61.6b
603392 Beijing Wantai Biological Pharmacy Enterprise
37.2x60.9%CN¥92.6b

Price-To-Sales vs Peers: 603392 is expensive based on its Price-To-Sales Ratio (37.2x) compared to the peer average (9.8x).

Price to Sales Ratio vs Industry

How does 603392's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
603716 Thalys Medical Technology Group
0.9xn/aUS$211.94m
No more companies available in this PS range
603392 37.2xIndustry Avg. 7.5xNo. of Companies9PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 603392 is expensive based on its Price-To-Sales Ratio (37.2x) compared to the CN Biotechs industry average (7.5x).

Price to Sales Ratio vs Fair Ratio

What is 603392's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603392 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio37.2x
Fair PS Ratio46.4x

Price-To-Sales vs Fair Ratio: 603392 is good value based on its Price-To-Sales Ratio (37.2x) compared to the estimated Fair Price-To-Sales Ratio (46.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603392 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥72.72
CN¥61.40
-15.6%
21.0%CN¥74.30CN¥48.50n/a2
Nov ’25CN¥72.50
CN¥61.40
-15.3%
21.0%CN¥74.30CN¥48.50n/a2
Oct ’25CN¥81.87
CN¥62.70
-23.4%
18.5%CN¥74.30CN¥51.10n/a2
Sep ’25CN¥70.99
CN¥63.55
-10.5%
19.6%CN¥76.00CN¥51.10n/a2
Aug ’25CN¥67.99
CN¥63.10
-7.2%
20.4%CN¥76.00CN¥50.20n/a2
Jul ’25CN¥65.54
CN¥70.40
+7.4%
27.1%CN¥89.50CN¥51.30n/a2
Jun ’25CN¥68.12
CN¥70.40
+3.3%
27.1%CN¥89.50CN¥51.30n/a2
May ’25CN¥68.28
CN¥70.40
+3.1%
27.1%CN¥89.50CN¥51.30n/a2
Apr ’25CN¥67.40
CN¥69.43
+3.0%
30.4%CN¥99.00CN¥51.30n/a3
Mar ’25CN¥75.01
CN¥69.43
-7.4%
30.4%CN¥99.00CN¥51.30n/a3
Feb ’25CN¥52.94
CN¥69.43
+31.2%
30.4%CN¥99.00CN¥51.30n/a3
Jan ’25CN¥75.13
CN¥62.40
-16.9%
45.3%CN¥99.00CN¥30.19n/a3
Dec ’24CN¥49.35
CN¥62.40
+26.4%
45.3%CN¥99.00CN¥30.19n/a3
Nov ’24CN¥45.15
CN¥62.40
+38.2%
45.3%CN¥99.00CN¥30.19CN¥72.503
Oct ’24CN¥47.98
CN¥78.50
+63.6%
26.1%CN¥99.00CN¥58.00CN¥81.872
Sep ’24CN¥48.91
CN¥78.50
+60.5%
26.1%CN¥99.00CN¥58.00CN¥70.992
Aug ’24CN¥70.20
CN¥97.50
+38.9%
11.8%CN¥109.00CN¥86.00CN¥67.992
Jul ’24CN¥66.77
CN¥97.50
+46.0%
11.8%CN¥109.00CN¥86.00CN¥65.542
Nov ’23CN¥89.57
CN¥146.27
+63.3%
0.3%CN¥146.71CN¥145.84CN¥45.152

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.51

7D

2.2%

1Y

7.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

7D

-2.4%

1Y

12.8%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.91

7D

-1.8%

1Y

14.6%